Substance Use Disorders Review – DEA MATE Act Requirement

Dr. Jack Krasuski is a nationally recognized leader in medical education and psychiatry. As the Founder and Executive Director of American Physician Institute for Advanced Professional Studies (API), he has helped thousands of physicians prepare for board certification and maintain clinical excellence through high-yield, evidence-based training. Dr. Krasuski is also the founder of MasterPsych, a platform offering comprehensive continuing medical education in psychiatry.

With a background in neuroimaging research at the National Institute on Aging, NIH, Dr. Krasuski brings academic rigor to his educational programs. He is widely known for his ability to distill complex psychiatric topics into clear, practical insights—whether teaching on treatment-resistant depression, anxiety disorders, or neuromodulation techniques. His work spans live conferences, online courses, and audio-based CME, including the popular CMEtoGO series.

Through initiatives like the Beat The Boards! exam prep and the MasterPsych platform, Dr. Krasuski continues to shape the future of psychiatric education, supporting clinicians in delivering compassionate, evidence-based care across diverse practice settings.

Karen Hartwell, MD is a psychiatrist and addiction specialist with extensive clinical and research experience in the treatment of substance use disorders, both with and without co-occurring psychiatric conditions. Her clinical work has included the care of individuals with complex opioid, alcohol, stimulant, and polysubstance use disorders, with a strong emphasis on evidence-based, patient-centered treatment approaches.

Dr. Hartwell’s research focuses on understanding the neurobiology of addiction and improving treatment outcomes for individuals with substance use disorders. She has collaborated on a wide range of studies involving opioids, cocaine, cannabis, alcohol, and tobacco use disorders, and has participated in multiple Phase 2–4 clinical trials investigating pharmacologic treatments and transcranial magnetic stimulation (TMS). Through her leadership in opioid-focused initiatives and her commitment to clinical innovation and research, Dr. Hartwell continues to play a key role in addressing the opioid epidemic and advancing addiction psychiatry.

Ximena Sanchez-Samper, MD is a board-certified addiction psychiatrist and Chief Medical Officer at New Horizons Medical, where she provides leadership in advancing high-quality, evidence-based care for patients with substance use disorders and co-occurring behavioral health needs. She earned her medical degree from Pontificia Universidad Javeriana in Bogotá, Colombia and completed her psychiatry residency at the Mayo Clinic in Rochester, Minnesota, followed by a fellowship in addiction psychiatry through a consortium including Massachusetts General Hospital, McLean Hospital, and Brigham and Women’s Hospital.

Dr. Sanchez-Samper has over two decades of experience treating adolescents, young adults, and adults affected by substance use disorders, and has advocated for the integration of medication-assisted treatment (MAT) into comprehensive addiction care. She has authored peer-reviewed publications and a book chapter on adolescent opioid use and has lectured nationally on identification, diagnosis, and treatment of substance use disorders. She also held a part-time instructional appointment at Harvard Medical School.

Kevin M. Gray, MD is a nationally recognized psychiatrist and researcher with expertise in addiction sciences and substance use disorders. His work focuses on advancing the understanding and treatment of addiction across the lifespan, integrating clinical care with translational and clinical research. Dr. Gray has played a leading role in developing and evaluating evidence-based interventions for substance use disorders and in fostering collaborative research partnerships that accelerate innovation and improve patient outcomes.

Scott M. Fishman, MD is an internationally recognized expert in pain medicine and pain management whose work focuses on improving the treatment of pain while promoting the safe and responsible use of pain therapies. He has held numerous national leadership roles dedicated to advancing pain care, including serving as past president of the American Academy of Pain Medicine and in leadership positions with major pain and medical organizations. Dr. Fishman is a prominent advocate for patients with pain, frequently advising policymakers, testifying before state legislatures and the U.S. Congress, consulting for federal agencies, and educating clinicians and the public. He is a widely sought-after speaker and media expert, regularly providing insight on pain management across national news and public health platforms.